Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03711032
Title Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

bladder urothelial carcinoma

Therapies

BCG solution + Pembrolizumab

BCG solution

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.